3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
30
Nivolumab
30
cabozantinib
20
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
belzutifan
13
lenvatinib
11
Axitinib
9
Specimen Handling
8
Sunitinib
7
durvalumab
5
CTLA-4 Antigen
5
tislelizumab
4
atezolizumab
4
Radiosurgery
4
Interleukin-2
4
Everolimus
4
Biopsy
4
Bevacizumab
4
pazopanib
3
avelumab
3
aldesleukin
3
Immunoglobulin G
3
Disulfides
3
palbociclib
2
fludarabine
2
entinostat
2
adavosertib
2
Surveys and Questionnaires
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Renal Cell
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled